Your gift is 100% tax deductible
Treatment of Children with Juvenile Myelomonocytic Leukemia (JMML)
Juvenile myelomonocytic leukemia (JMML) is rare so it has been hard to study which treatment might be best. There is no clear single best chemotherapy treatment for this leukemia.
On this page
Common treatment approaches for JMML
A stem cell transplant is the treatment of choice when possible, as it offers the best chance to cure JMML. Sometimes, even if the leukemia recurs, a second stem cell transplant can be helpful.
Because JMML is hard to treat with current chemo drugs, taking part in a clinical trial looking at newer drugs may be a good option for children who cannot get a stem cell transplant.
- Written by
- References
Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).
National Cancer Institute. Juvenile Myelomonocytic Leukemia Treatment (PDQ). 2024. Accessed at https://www.cancer.gov/types/leukemia/hp/child-aml-treatment-pdq/childhood-jmml-treatment-pdq on May 12, 2025.
Niemeyer CM, Flotho C, Lipka DB, et al. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021;5(14):2901-2908.
Rau RE, Loh ML. Chapter 17B: Myeloproliferative Neoplasms of Childhood. In: Blaney SM, Adamson PC, Helman LJ, eds. Pizzo and Poplack’s Pediatric Oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2021.
Last Revised: July 22, 2025
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
American Cancer Society Emails
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
